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Abstract: Helicobacter pylori infection remains widespread internationally, with a definite 
morbidity and mortality. The efficacy of standard 7–14 day triple therapies is decreasing, mainly 
due to increasing primary bacterial resistance to antibiotics. Currently, the most effective treat-
ments are either the sequential regimen or the concomitant therapy. Different patents have been 
registered showing high bactericidal effects in vitro, some of which are active against clarithro-
mycin- and metronidazole-resistant strains, even at low pH values. Among these novel molecules, 
benzimidazole-derivatives, polycyclic compounds, pyloricidin, and arylthiazole analogues seem 
to be the more promising. The identification of essential genes for either bacterial colonization 
or growth represents a route for potential target therapies in the near future.
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Introduction
Despite the evidence that H. pylori prevalence is declining in developed countries, the 
infection remains widespread internationally, with a definite morbidity and mortality.1 
Indeed, H. pylori is the main cause of nonulcer dyspepsia, peptic ulcer disease, and 
gastric tumors, including both low-grade mucosa-associated lymphoid tissue lymphoma 
and adenocarcinoma.2,3 Among the extra-digestive diseases, data show a significant 
association between H. pylori infection and both idiopathic thrombocytopenic purpura 
and idiopathic iron deficiency anemia.4,5 H. pylori infection is generally acquired in 
childhood, and it persists throughout life. Spontaneous resolution is rare, and so a tar-
geted therapy is needed. H. pylori colonizes a kind of biological niche – ie, under the 
gastric mucous layer, strongly attached to epithelial cells and even within cells – where 
antibiotic action is impaired, and so, curing such an infection is difficult. Different 
antibiotic combinations, administered together with a proton pump inhibitor (PPI), 
have been proposed in the last decades. Unfortunately, no available therapy is able to 
eradicate H. pylori in all treated patients. Therefore, new drugs and novel therapeutic 
approaches are needed.
Current therapies
The combination of a PPI with clarithromycin and amoxicillin or metronidazole is 
the most common first-line therapy regimen. However, current European guidelines 
confirm the use of standard 7-day triple therapy only in those areas where primary 
clarithromycin resistance is lower than 15%–20%, whilst a prolonged 14-day regi-
men should be used where bacterial resistance rate is higher.6 Nevertheless, data from 
two large trials found that after completion of the prolonged 14-day triple therapy, 
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the eradication rate was only 70% in nonulcer dyspepsia 
patients, and 81.7% in peptic ulcer patients.7,8 Therefore, 
different therapeutic approaches are needed. The sequential 
therapy was first introduced in Italy in 2000.9 This regimen 
is a 10-day therapy, including a simple dual therapy with 
a PPI plus amoxicillin 1 g (both twice daily) given for the 
first 5 days, followed by a triple therapy including a PPI, 
clarithromycin 500 mg, and tinidazole 500 mg (all given 
twice daily) for the remaining 5 days.
The first comprehensive, pooled-data analysis of sequen-
tial therapy, which included over 1,800 Italian patients, 
found an eradication rate as high as 93.5%.10 Moreover, the 
high efficacy of such a therapy regimen has been confirmed 
in several other countries, including Israel, Korea, Panama, 
Poland, Romania, Spain, Taiwan and Thailand, but not in Iran 
or Latin America.11−17 Different trials compared the efficacy 
of sequential therapy with that of standard triple therapies. 
A meta-analysis showed that a sequential regimen was 
better than standard 7–10 day triple therapies.18 These data 
have been updated, and the eradication rates following the 
sequential therapy (2,454/2,853; 86%; 95% CI: 84.7–87.3) 
remained distinctly higher compared to that of triple therapies 
(2,320/3,079; 75.3%; 95% CI: 73.8–76.9).19
Some recent studies found that a levofloxacin- instead of 
clarithromycin-based sequential therapy also appears highly 
effective.20,21 However, such modified sequential therapy pre-
cludes the use of a levofloxacin-based second-line therapy, 
thereby complicating any successive therapeutic approach in 
patients who fail eradication therapy.22,23 Moreover, primary 
resistance to levofloxacin is quickly increasing worldwide, 
with prevalence values of 17% in Brazil, 16.8% in Belgium, 
22.1% in Germany, 18% in Hong Kong, 19.1% in Italy, 
14.3% in Japan, and 21.5% in Korea.22 Therefore, levo-
floxacin should be used with caution in a first-line therapy 
regimen.24
Concomitant therapy comprises a PPI plus amoxicil-
lin, clarithromycin, and metronidazole, given all together. 
This therapy was first introduced as an alternative to standard 
triple therapies more than 10 years ago, and the original 
duration of therapy was only 5 days. A recent meta-analysis 
of 15 studies found a high efficacy of this regimen, with 
an eradication rate of 90%. However, it was noted that the 
eradication rate increased with therapy duration, being 85% at 
3 days, 88% at 4 days, 89% at 5 days, 93% at 7 days, and 92% 
at 10 days.25 Another meta-analysis of 9 studies including 
only 7-day concomitant therapy calculated eradication rates 
of 90% at ITT and 93% at PP analysis.26 Pooled estimates of 
the five randomized controlled trials showed the superiority 
of concomitant therapy over triple therapy (OR: 2.86; 95% 
CI: 1.73–4.73).26
Future therapies
Although the contributing factors differ,27 therapy failure 
mainly depends on primary resistance to different antibiotics 
(eg, clarithromycin), which is increasing worldwide.28 It is 
thought that only new classes of antimicrobials with novel 
mechanisms of action can fully address the increasing drug 
resistance.29 In the last decade, several patents of new anti-
biotics have claimed potential activity against H. pylori.30−32 
Of note, some molecules have shown a very high bactericidal 
level of activity against H. pylori in vitro, including those 
strains with primary clarithromycin and/or metronidazole 
resistance. In addition, some molecules preserve antibacte-
rial activity even at low pH values, a clear advantage for 
H. pylori treatment, considering that they must act in gastric 
acid. In particular, different benzimidazole-derivatives and 
polycyclic compounds have been patented, which are highly 
effective against H. pylori.30 Pyloricidin A, B, and C – a 
family of natural antibiotics – have exhibited a potent and 
highly selective bactericidal activity against H. pylori, 
with an MIC90 value of 0.013 mg/L.30 In addition, among 
the arylthiazole analogues, the thienylthiazole derivative 
44 exhibited the strongest activity, with MIC90 values as low 
as 0.0065 mg/L.30 Of note, some isothiazole derivatives have 
been found to enable a potent inhibition of bacterial urease 
activity in vitro, constituting a potential “targeted” therapy for 
H. pylori infection.31 The list of potential useful molecules is 
provided in Table 1, while in Table 2 there are several plant 
extracts with anti-H. pylori activity in vitro.30−34 Therefore, 
it is likely that more powerful drugs will be available in the 
near future to treat H. pylori infection.
Table 1 New molecules with H. pylori activity
Molecule MIC90 value  
(mg/L)
pH  
activity
Cla-R/ 
Met-R
Arylthiazole derivative 44 0.0065 NA NA/NA
Benzimidazole derivatives
  Y-754 
  BAS-118
0.025 
0.013
5.5 
NA
NA/NA 
Yes/yes
I-valnemulin 0.0125–0.5 NA Yes/yes
Mupirocin 0.12–0.25 5.4 NA/NA
Polycyclic compound 0.2–0.39 NA NA/NA
Pyloricidin (A, B, and C) 0.013 NA NA/NA
Rifampin 0.032–2 NA Yes/yes
Notes:  MIC90:  minimal  inhibitory  concentration;  Cla-R:  efficacy  towards 
clarithromycin resistant strains; Met-R: efficacy towards metronidazole resistant 
strains.
Abbreviation: NA, not available.
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Many studies have addressed the identification of novel 
therapeutic targets (eg, bacterial proteins, mechanisms, 
genes required for growth and/or colonization, etc). Further 
investigation of anti-H. pylori therapies have addressed the 
identification of essential genes required for in vitro bacte-
rial survival, or genes essential for mucosal colonization.35,36 
Indeed, several studies have shown large numbers of genes 
involved in cellular motility that are required for coloniza-
tion or growth, demonstrating that they represent a potential 
target by H. pylori-specific anti-infective agents. Additional 
functions potentially susceptible to therapeutic intervention 
include cellular processes like chemotaxis, protein folding, 
regulation, genetic information processing, and resistance to 
acid and oxidative stresses.37 There are several genes that have 
been evaluated as potential therapeutic targets, most of them 
encoded for proteins which form biochemical pathways, or 
urease–related genes that are essential for host   colonization. 
There are also many gene-encoding proteins required 
for bacterial growth that have been studied as potential thera-
peutic targets, but further evaluations are needed.38
Conclusion
The available antibiotics active against H. pylori in vivo are 
very rare, and new molecules are needed. The current most 
effective combination of these drugs is both sequential and 
concomitant therapy. Different patents have been registered 
showing high bactericidal effects in vitro, some of which are 
active against clarithromycin- and metronidazole-resistant 
strains, even at low pH values. Therefore, the search for 
novel antibacterial therapies against H. pylori is a “work in 
progress” driven by the goal of preventing gastric cancer, and 
by worldwide increasing antibiotic resistance.
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